DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 8, 2022
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its third quarter 2022 financial results on Tuesday, November 8,…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Omidria® for Intracameral Use During Cataract Surgery or Intraocular Lens Replacement
– Transaction adds a well-established ophthalmology product that generates substantial near-term cash flows, with long-term structural growth anticipated – – Third transaction of 2022 with…
DRI Healthcare Trust Provides Update on Natpara Royalty
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that, based on its ongoing review of its royalty entitlement on Natpara (the “Natpara Royalty”), DRI has…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Omidria® for Intracameral Use During Cataract Surgery or Intraocular Lens Replacement
– Transaction adds a well-established ophthalmology product that generates substantial near-term cash flows, with long-term structural growth anticipated – – Third transaction of 2022 with…
DRI Healthcare Trust Provides Update on Natpara Royalty
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that, based on its ongoing review of its royalty entitlement on Natpara (the “Natpara Royalty”), DRI has…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Currently Approved for the Treatment of Ovarian Cancer with Additional Indications Under Development
– Zejula’s multiple pipeline indications offer significant upside potential – – Transaction builds on DRI’s history of investing in innovative oncology therapies – – Long-term asset with…
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Currently Approved for the Treatment of Ovarian Cancer with Additional Indications Under Development
– Zejula’s multiple pipeline indications offer significant upside potential – – Transaction builds on DRI’s history of investing in innovative oncology therapies – – Long-term asset with…
DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that the Trust will participate in the following investor conferences in August and September: Canaccord…
DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that the Trust will participate in the following investor conferences in August and September: Canaccord…
DRI Healthcare Trust Reports Second Quarter 2022 Results
– Continued strong financial results and cash generation from existing assets – – Addition of pegcetacoplan to royalty portfolio subsequent to quarter end – TORONTO, Aug. 3, 2022 /CNW/ – DRI…